Adicet Bio (ACET) vs Edesa Biotech (EDSA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Edesa Biotech (EDSA) has outperformed Adicet Bio (ACET) over the past year, gaining 34.6% versus a loss of 54.7%. Over five years, EDSA leads with a -93.3% price change compared with -95.2% for ACET. Adicet Bio is the larger company by market cap ($53.7 million vs $49.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACET | EDSA |
|---|---|---|
| Share price | $5.74 | $3.66 |
| Market cap | $53.73M | $49.45M |
| 1-day change | -7.12% | -5.79% |
| YTD return | -26.60% | +157.75% |
| 1-year return | -54.72% | +34.56% |
| 5-year return | -95.20% | -93.31% |
| EPS (TTM) | $-10.42 | $-1.72 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.44 | $20.32 |
| 52-week low | $5.55 | $0.72 |
| Distance from 52-week high | -67.09% | -81.99% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +506.79% | +346.17% |
| Average volume | 166.29K | 62.13K |
| Shares outstanding | 9.36M | 13.51M |
| Employees | 102 | 17 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EDSA has outperformed ACET by 89.3 percentage points over the past year.
About Adicet Bio
ACET stock →Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases.
Healthcare · Biotechnology · 102 employees
About Edesa Biotech
EDSA stock →Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis.
Healthcare · Biotechnology · 17 employees
ACET vs EDSA FAQ
Which is bigger, Adicet Bio or Edesa Biotech?
Adicet Bio (ACET) is larger, with a market capitalization of $53.73M compared with $49.45M for Edesa Biotech (EDSA).
Which stock has performed better over the past year, ACET or EDSA?
EDSA returned +34.56% over the past 12 months, compared with -54.72% for ACET (price return, excluding dividends). Past performance does not predict future results.
Are Adicet Bio and Edesa Biotech in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.